In summary, we expect that SBTI, as a naturally derived trypsin inhibitor, has the potential to inhibit SARS-CoV-2 infection via ACE2, TMPRSS2, and CD147 pathways, which provides evidence for the development of a prospective functional food for COVID-19 therapy. The gene discussed is TMPRSS2; the disease is COVID-19.